Skip to main content

News

News

Press Release

Complement Therapeutics Announces the Establishment of Medical Advisory Board 

Munich, Germany – 14th December 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...
Read More
Uncategorized

Complement Therapeutics Appoints Dr. Matthias Hebben, as Chief Technology Officer

Munich, Germany – 5th December 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...
Read More
Press Release

Complement Therapeutics Enrols First US Participant in the Non-interventional i-GAIN Study of People Diagnosed with Geographic Atrophy

Munich, Germany – 09 November 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...
Read More
Press Release

Complement Therapeutics Appoints Dr Parisa Zamiri MD, as Chief Medical Officer

Munich, Germany – 3rd August 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...
Read More
Press Release

Complement Therapeutics Unveils State-of-the-Art Laboratory at Stevenage Bioscience Catalyst 

Munich, Germany – 13th June 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...
Read More
Press Release

Complement Therapeutics Appoints Dominic Moreland as Chief Financial Officer 

Munich, Germany – 27th April 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...
Read More
Press Release

Complement Therapeutics to Present Preclinical Proof of Concept Data on CTx001 at the 2023 Association for Research in Vision and Ophthalmology Congress

Munich, Germany – 20th April 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...
Read More
Press Release

Complement Therapeutics Secures 72 Million in Series A Financing to Advance Novel Therapies Targeting Complement-Mediated Diseases

Round led by Gimv, a Belgian based private equity and venture capital firm Round comes just 1 year after raising...
Read More
Press Release

Complement Therapeutics Announces Strategic Manufacturing Collaboration with Pharmaron

London, UK - March 29th 2023 - Complement Therapeutics Ltd (CTx) and Pharmaron are delighted to announce a strategic partnership...
Read More
Press Release

Complement Therapeutics Enrols First Patient in Non- interventional i-GAIN Study of People Diagnosed with Geographic Atrophy

London England – 09 February 2023 - Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company, today announced enrolment of...
Read More
Press Release

Complement Therapeutics secures Innovate UK EDGE funding to collaborate with the Cell and Gene Therapy Catapult on regulatory strategy for CTx001

The Innovate UK EDGE grant funding is awarded to innovative companies looking to benefit from the expertise provided by Catapults...
Read More
Press Release

MHRA awards Complement Therapeutics Innovation Passport for CTx001 to accelerate Gene Therapy for Geographic Atrophy

MHRA granted Complement Therapeutics an Innovation Passport under the new accelerated Innovative Licensing and Access Pathway (ILAP)ILAP is designed to...
Read More
Press Release

Complement Therapeutics Announces the Establishment of its Clinical & Scientific Advisory Board

London, England – 27th September 2022 - Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company, today announced the formation...
Read More
Press Release

Complement Therapeutics Ltd announces appointment of Dr Dennis Keefe as Chief Scientific Officer

London, England – 10th August 2022 - Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company focused on the research...
Read More
Press Release

Complement Therapeutics Ltd announces appointment of Steve Axon to its Board of Directors

Complement Therapeutics Ltd announces appointment of Steve Axon to its Board of Directors London, England – 18th July 2022 -...
Read More
Press Release

Complement Therapeutics Ltd raises EUR 5 Million Seed Financing by BGV and Forbion and appoints Dr Rafiq Hasan as CEO

Next-generation Complement Therapeutics based on the role of Factor H-related proteins in complement-mediated diseases Company emerges out of stealth mode...
Read More